. 2012 Jan 3;33(1):82–90. doi: 10.1038/aps.2011.165

Table 2. Effects of AVE8134, fenofibrate, and rosiglitazone in female hApo A1 mice on body weight (bw), relative liver weight, relative heart weight, and Apo E. ^bP<0.05 vs vehicle control.

Treatment	Dose (mg/kg)	Weight gain (g)	Food consumption (g/d)	Liver weight (% bw)	Heart weight (% bw)	Apo E (mg/L)
Control	No treatment	1.28±0.25	3.52±0.08	4.34±0.07	0.45±0.01	0.95±0.07
	Vehicle	0.57±0.18	3.19±0.14	4.58±0.12	0.45±0.01	1.04±0.09
AVE8134	1	0.89±0.43	3.24±0.23	4.69±0.06	0.44±0.01	1.25±0.10
	3	0.96±0.55	3.29±0.03	5.40±0.11	0.44±0.01^b	2.00±2.20^b
	10	0.96±0.13	3.38±0.15	6.95±0.13	0.45±0.01^b	3.22±0.17^b
	30	1.48±0.31	3.23±0.05	7.73±0.13	0.45±0.01^b	3.53±0.08^b
Fenofibrate	10	0.76±0.16	3.40±0.10	5.09±0.06	0.47±0.01^b	1.49±0.07
	30	−0.14±0.43	3.15±0.09	6.12±0.16	0.46±0.01^b	2.32±0.29^b
	100	1.49±0.23	3.25±0.05	7.46±0.20	0.43±0.01^b	3.18±0.14^b
Rosiglitazone	3	0.81±0.26	3.49±0.17	4.60±0.09	0.47±0.02	1.29±0.09
	10	0.57±0.23	3.25±0.15	4.68±0.11	0.49±0.02	1.31±0.16

Table 2. Effects of AVE8134, fenofibrate, and rosiglitazone in female hApo A1 mice on body weight (bw), relative liver weight, relative heart weight, and Apo E. bP<0.05 vs vehicle control.